MA53623A - Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k) - Google Patents
Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k)Info
- Publication number
- MA53623A MA53623A MA053623A MA53623A MA53623A MA 53623 A MA53623 A MA 53623A MA 053623 A MA053623 A MA 053623A MA 53623 A MA53623 A MA 53623A MA 53623 A MA53623 A MA 53623A
- Authority
- MA
- Morocco
- Prior art keywords
- ube2k
- inhibition
- cancer
- treatment
- methods
- Prior art date
Links
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 title 2
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729348P | 2018-09-10 | 2018-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53623A true MA53623A (fr) | 2021-07-21 |
Family
ID=69778426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053623A MA53623A (fr) | 2018-09-10 | 2019-09-10 | Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210252036A1 (fr) |
| EP (1) | EP3849543A4 (fr) |
| JP (2) | JP2022500378A (fr) |
| KR (1) | KR20210057121A (fr) |
| CN (1) | CN112996504A (fr) |
| AU (1) | AU2019339896A1 (fr) |
| BR (1) | BR112021004417A2 (fr) |
| CA (1) | CA3112191A1 (fr) |
| IL (1) | IL281327A (fr) |
| MA (1) | MA53623A (fr) |
| MX (1) | MX2021002818A (fr) |
| SG (1) | SG11202102417TA (fr) |
| WO (1) | WO2020055906A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11091447B2 (en) * | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
| CN118488837A (zh) * | 2021-11-17 | 2024-08-13 | 布普格生物制药公司 | 用于治疗胃癌的化合物 |
| CN119770494A (zh) * | 2025-01-23 | 2025-04-08 | 中国人民解放军空军军医大学 | Ptc-209在制备治疗肝癌药物中的应用 |
| CN121197415B (zh) * | 2025-11-26 | 2026-02-03 | 山东大学齐鲁医院 | Cpsf7作为卵巢癌治疗与预后靶点的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1784646B1 (fr) * | 2004-08-11 | 2012-06-13 | Albert Einstein College Of Medicine Of Yeshiva University | Procédé d'identification de metastases dans des cellules motiles |
| CN101583622B (zh) * | 2006-11-02 | 2012-11-07 | 舒泰神（北京）生物制药股份有限公司 | 用于破坏与泛素化相关的酶的相互作用的抑制剂和其应用 |
| KR100919832B1 (ko) * | 2009-05-15 | 2009-10-01 | 고려대학교 산학협력단 | Ｈｉｐ―２ 유전자 발현을 억제하여 암세포의 방사선에 대한 민감도를 증진하는 방법 |
| WO2014094138A1 (fr) * | 2012-12-21 | 2014-06-26 | Universite De Montreal | Procédés de criblage pour l'identification de composés inhibiteurs de l'activité d'enzymes e2 par la stabilisation de complexes ubiquitine-e2 non covalents et applications pharmaceutiques associées aux inhibiteurs d'e2 |
| KR101525122B1 (ko) * | 2013-08-05 | 2015-06-03 | 광주과학기술원 | Ｕｂｂ 넉다운에 의한 암의 예방 또는 치료 |
| EP3107577B1 (fr) * | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Traitement d'une maladie par induction d'une réponse immune à des cellules exprimant le trop-2 |
| JP6647315B2 (ja) * | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
-
2019
- 2019-09-10 MA MA053623A patent/MA53623A/fr unknown
- 2019-09-10 SG SG11202102417TA patent/SG11202102417TA/en unknown
- 2019-09-10 EP EP19861199.8A patent/EP3849543A4/fr active Pending
- 2019-09-10 KR KR1020217010620A patent/KR20210057121A/ko not_active Ceased
- 2019-09-10 BR BR112021004417-5A patent/BR112021004417A2/pt not_active Application Discontinuation
- 2019-09-10 CA CA3112191A patent/CA3112191A1/fr active Pending
- 2019-09-10 CN CN201980073592.0A patent/CN112996504A/zh active Pending
- 2019-09-10 AU AU2019339896A patent/AU2019339896A1/en not_active Abandoned
- 2019-09-10 MX MX2021002818A patent/MX2021002818A/es unknown
- 2019-09-10 JP JP2021513242A patent/JP2022500378A/ja active Pending
- 2019-09-10 WO PCT/US2019/050465 patent/WO2020055906A1/fr not_active Ceased
- 2019-09-10 US US17/274,405 patent/US20210252036A1/en active Pending
-
2021
- 2021-03-08 IL IL281327A patent/IL281327A/en unknown
-
2024
- 2024-09-09 JP JP2024155233A patent/JP2025003968A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019339896A1 (en) | 2021-04-08 |
| WO2020055906A1 (fr) | 2020-03-19 |
| SG11202102417TA (en) | 2021-04-29 |
| CN112996504A (zh) | 2021-06-18 |
| IL281327A (en) | 2021-04-29 |
| KR20210057121A (ko) | 2021-05-20 |
| BR112021004417A2 (pt) | 2021-06-01 |
| US20210252036A1 (en) | 2021-08-19 |
| MX2021002818A (es) | 2021-07-15 |
| WO2020055906A8 (fr) | 2021-01-07 |
| EP3849543A1 (fr) | 2021-07-21 |
| JP2022500378A (ja) | 2022-01-04 |
| JP2025003968A (ja) | 2025-01-14 |
| CA3112191A1 (fr) | 2020-03-19 |
| EP3849543A4 (fr) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564C0 (fr) | Dérivés de pyridazine pour le traitement du cancer | |
| EP3947715A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3894392A4 (fr) | Compositions et procédés pour le traitement du cancer | |
| MA53623A (fr) | Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k) | |
| EP4610279A3 (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MX2017013207A (es) | Inhibidores de bromodominio. | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| MA51418A (fr) | Inhibiteurs de glycolate oxydase pour le traitement de maladies | |
| EP3908601A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| EP3833344A4 (fr) | 2-arylbenzimidazoles utiles en tant qu'activateurs de ppargc1a pour le traitement de maladies neurodégénératives | |
| EP3630080A4 (fr) | Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer | |
| EP4085053A4 (fr) | Traitement du cancer avec des inhibiteurs de cdk12/13 | |
| EP3775171A4 (fr) | Procédés de traitement d'un cancer résiduel minimal | |
| IL288408A (en) | Methods of treating urinary system cancers | |
| EP4058041C0 (fr) | Compositions pour le traitement de lésions épithéliales | |
| DK3924340T3 (da) | Indazolyl-isoxazolderivater til behandlingen af sygdomme såsom kræft | |
| MA54465A (fr) | Inhibiteurs de cxcr7 destinés au traitement du cancer | |
| MA55531A (fr) | Procédés pour le traitement de béta-thalassémie | |
| EP3849544A4 (fr) | Polythérapie pour le traitement du cancer de la prostate | |
| EP3442564A4 (fr) | Composition de proenzymes pour le traitement du cancer | |
| EP3897650A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP4341271A4 (fr) | Compositions pour traitement d'affections neurodégénératives |